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Abstract – Marek’s disease virus (MDV) is an alphaherpesvirus that causes lethal T-cell lymphomas in
chickens. MDV is unique in that it harbors two copies of a viral telomerase RNA subunit (vTR) in its
genome exhibiting 88% sequence identity to the chicken orthologue, chTR. The minimal telomerase
ribonucleoprotein complex consists of a protein subunit with reverse transcriptase activity (TERT) and TR.
Physiologically, the complex compensates for the progressive telomere shortening that occurs during
mitosis and is involved in the process of cellular immortalization. Previous studies showed that MDV vTR
performes an auxiliary function during oncogenesis. Comparative in vitro analysis of the viral and chicken
TR promoters revealed that the vTR promoter (PvTR) was up to 3-fold more efﬁcient than the chTR
promoter (PchTR) in avian cells and that the stronger transcriptional activity of PvTR resulted largely from
an E-box located two nucleotides downstream of the transcriptional start site of the vTR gene. To test the
hypothesis that PvTR is required for vTR expression and, hence, efﬁcient tumor formation, we generated a
recombinant virus, vPchTR
+/+, in which the vTR promoter was replaced by that of chTR. In vivo, growth of
vPchTR
+/+ was indistinguishable from that of parental virus; however, tumor induction was reduced by
> 50% and lymphomas were smaller and less disseminated when compared to those induced by parental
virus. We concluded that PvTR is not required for lytic replication in vivo but is essential for efﬁcient
transcription of vTR and thereby critical for efﬁcient MDV lymphoma formation.
MDV / lymphoma / viral telomerase RNA / promoter control
1. INTRODUCTION
Marek’s disease virus (MDV) is an avian
herpesvirus that causes Marek’s disease (MD),
a highly contagious and malignant T-cell lym-
phoma in chicken. MDV is a member of the
genus Mardivirus within the Alphaherpesviri-
nae subfamily [4, 5]. The MDV genome is
approximately 180 kb in length and consists
of a unique long (UL) and a unique-short
(US) segment, each of which are ﬂanked by
inverted repeats, called terminal and internal
repeats long (TRL and IRL), and terminal and
internal repeats short (TRS and IRS), respec-
tively [17, 37]. MD is characterized by immu-
nosuppression, neurological symptoms and the
induction of T-cell lymphomas in the viscera
as early as 2 weeks post-infection (p.i.).
According to the current model of pathogenesis,
infection is initiated in the respiratory tract after
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Article published by EDP Sciencesinhalation of infectious virus where phagocytic
cells, macrophages and/or dendritic cells (DC),
become infected. Within 24 h after initial
uptake, virus is detectable in the bursa of Fabri-
cius. Lytic replication occurs in many cell types,
including B and T cells, but only T cells, pre-
dominantly of the CD4+ phenotype, harbor
latent MDV that can ultimately result in trans-
formation [2, 29].
Apart from its signiﬁcance to animal health,
MDV provides a good model to study virus-
induced oncogenesis. It is well established that
MDVencodes the oncoprotein Meq, which has
been shown to directly cause transformation of
cells. Recently, another viral product encoding a
telomerase RNA component (TR), termed vTR,
has been reported to play a role in the develop-
ment, maintenance, and dissemination of MDV-
induced tumors [36]. MDV contains in its
genome two identical copies of vTR with one
copy contained in both the TRL and IRL [7].
TERT, a reverse transcriptase, and its partner
TR represent the catalytic core of the telome-
rase, a eukaryotic ribonucleoprotein complex
that compensates by the addition of telomeres
for the inability of DNA polymerase to copy
the 30 endoflinear chromosomes [1].Telomeres
are essential nucleoprotein structures of all
eukaryotic chromosomes, protecting them from
exonuclease degradation and end-to-end chro-
mosomal fusions. Telomerase replicates telo-
meres by utilizing TERT and its intrinsic RNA
template TTAGGG within TR to add multiple
repeats onto the ends of chromosomes. This
DNA elongation compensates for the erosion
of telomeres during each round of DNA replica-
tion[1,40].Telomeraseactivityisnotdetectable
in normal somatic cells, but is strongly
expressed during fetal development and consti-
tutively expressed in highly proliferative cells
such as germ line cells, stem cells, and lympho-
cytes [11, 38]. Hence, telomere erosion limits
the replicative capacity of somatic cells [9, 20]
and when telomeres shorten to a critical length,
cells enter a stage termed replicative senescence
where cell division is prevented [10].
Telomerase levels are elevated in more than
85%ofhumancancers.Hightelomeraseactivity
and stabilization of telomere lengths have also
been detected in spontaneously-induced tumors
or virus-transformed cell lines [16, 31, 32].
In cells infected by oncogenic viruses, an
increase in telomerase activity has been associ-
ated with an up regulation of the TERTcompo-
nentthrougha complex network oftranscription
factors and cis-acting sequences [22].
MDV is unique among viruses because it is
the only known virus encoding its own telome-
rase RNA. The MDV RB-1B strain vTR is a
443 nt RNA that displays 88% sequence
homology to that of the chicken TR gene
(chTR), suggesting that it was pirated from
the chicken genome [7]. Functionality of vTR
has been demonstrated in TR deﬁcient murine
cells in which vTR is capable of supporting tel-
omerase activity by interacting with TERT
more efﬁciently than chTR [8]. The role of
vTR in MDV lymphomagenesis was also dem-
onstrated as deletions of the CR1-2 region in
both copies of vTR in the oncogenic strain
MDV RB-1B resulted in a 60% reduction of
tumors in infected chickens [36]. Lymphomas
in chickens challenged with vTR deletion
viruses were smaller in size and less widely
disseminated. Thus, vTR exhibits auxiliary
functions during oncogenesis, enhancing the
incidence and severity of lymphoma caused
by MDV [36]. Also, up regulation of telome-
rase activity during MDV infection was associ-
ated with an increase in vTR gene expression
[33]. In vitro analyses showed that up regula-
tion of vTR expression is in fact related to a
stronger transcriptional activity of the vTR pro-
moter (PvTR), that was associated to an E-box
located two nucleotides downstream from the
transcriptional start site of the vTR gene.
The c-Myc oncoprotein has been implicated
in the transcriptional regulation of vTR, which
in turn can be controlled through Meq activity
[19, 24, 33].
Here, we tested the hypothesis that
the authentic PvTR is required for efﬁcient
and timely coordinated expression of vTR
and, hence, efﬁcient tumor formation. By
generating a recombinant virus, vPchTR
+/+,i n
which PvTR was replaced by its chicken
counterpart, we observed that lytic replication
of vPchTR
+/+ in vivo was indistinguishable
from that of parental virus. However, tumor
induction was reduced by more than 50% and
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widely disseminated when compared to those
induced by parental virus. These data indicated
that the PvTR is also essential for efﬁcient
MDVlymphomaformation,mostlikelythrough
high level vTR expression.
2. MATERIALS AND METHODS
2.1. Cells and viruses
Chicken embryo cells were prepared from 11-
day-old embryos as previously described [30]a n d
maintained in minimal essential medium (Biochrom,
Berlin, Germany) supplemented with 10% fetal
bovine serum (Biochrom) and grown at 37  Ci na
5% CO2 atmosphere.
The mutant in which the PvTR was exchanged
with the chTR promoter (PchTR) was termed
vPchTR
+/+ and the revertant virus in which the vTR
promoter was reinserted was termed vPvTR
+/+.T h e
mutants were generated from pRB-1B, an infectious
bacterial artiﬁcial chromosome (BAC) containing
the genome of the highly virulent RB-1B strain [26]
that had been restored for horizontal transmission
[13]. Parental vRB-1B and recombinant viruses
vPchTR
+/+ and vPvTR
+/+ were reconstituted by
CaPO4 co-transfection of BAC DNA with
pCAGGS-NLS/Cre [12, 15], a plasmid expressing
the Cre enzyme for excision of mini-F sequences
usingloxPsites,intoCEC.After2to4passages,virus
stocks were prepared and frozen in liquid nitrogen
until further use.
2.2. Bacteria, plasmids and BAC
All plasmids were constructed and maintained in
Escherichia coli DH10B cells grown at 37  Ci n
Luria-Bertani (LB) medium unless otherwise stated.
BAC maintenance and Red recombinations were
performed in E. coli strain GS1783 (kindly provided
by Dr Gregory Smith, Northwestern University,
Chicago, IL, USA) harboring pRB-1B and contain-
ing a k prophage encoding the recombination
enzymes Exo, Beta, and Gam [35]. The PvTR
sequences were replaced by the PchTR sequences
in pRB-1B genome by two-step Red mutagenesis,
following the strategy described for introduction of
long sequence stretches [35]. DNA extracted from
CEC was used as a template to PCR amplify
the PchTR with primers PchTR-F and PchTR-R
(Tab. I). The PCR product was digested with HindIII
and EcoRI and cloned into the corresponding sites of
plasmid pUC18 resulting in recombinant plasmid
pUC18-PchTR. The second step was the construction
of the universal transfer plasmid pEPkan-PchTR,
which harbors a transfer cassette, termed PchTR-I-
SceI-aphAI, and contains the sequences of interest
(PchTR) with an aphAI sequence that confers
kanamycin resistance (kan
r), an adjoining I-SceI site,
and a duplication of a short sequence of PchTR. To
this end, the I-SceI-aphAI fragment was PCR
ampliﬁed from plasmid pEPkan-S [35]u s i n gp r i m e r s
pEPchTRpromIN-F and pEPchTRpromIN-R (Tab. I).
After gel puriﬁcation, the PCR product was cloned
into plasmid pUC18-PchTR using a singular PstI site
located in the PchTR fragment. The cassette PchTR-
I-SceI-aphAI was ampliﬁed from the plasmid
pEPkan-PchTR using primers PvTRexch-Forw and
PvTRexch-Rev and then introduced into pRB-1B
by a ﬁrst Red recombination after electroporation of
100 ng of the puriﬁed fragment into GS1783 harbor-
ing the BAC. The insertion of the transfer cassette
resulted in duplication of a short sequence stretch
within PchTR, which was used to remove the aphAI
resistance gene by a second Red recombination after
induction of the restriction endonuclease I-SceI [35].
The exact same procedure was repeated in the second
repeat-long region, resulting in introduction of two
copies of PchTR into pRB-1B; the ﬁnal construct
was termed pPchTR
+/+.
To reintroduce PvTR sequences into the
pPchTR
+/+ genome, PvTR was ampliﬁed with prim-
ers Resc-PvTR-F and Resc-PvTR-R (Tab. I). The
PvTR fragment was digested with EcoRI and HindIII
and cloned into pcDNA3 (Invitrogen, Darmstadt,
Germany) generating recombinant vector pcDNA3-
PvTR. Primers pEP-PvTR-F and pEP-PvTR-R
(Tab. I) were used for PCR ampliﬁcation of the
I-SceI-aphAI cassette from pEPkan-S and transferred
into the unique BamHI site of pcDNA3-PvTR gener-
ating the transfer plasmid pEPkanPvTR. From this
vector, a fragment containing the PvTR sequence
and the I-SceI-aphAI cassette was ampliﬁed with
primers EPrescPvTR-F and Resc-PvTR-R (Tab. I)
a n du s e df o rt h er e p a i ro fp P c h T R
+/+ by two-step
Red recombination exactly as described above.
2.3. Southern blot analysis
Probes used in Southern blot analysis were pre-
pared using the PCR DIG Probe Synthesis kit (Roche
Applied Science, Mannheim, Germany) according
to the manufacturer’s protocols. The DIG-labeled
kan
r probe was ampliﬁed from plasmid pEPkan-S
using speciﬁc primers Kan-F and Kan-R (Tab. I).
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with primers SB-PchTR-forw and SB-PchTR-rev
(Tab. I). For Southern blot analyses, DNA digested
with PstIw a ss e p a r a t e db y0 . 8 %a g a r o s eg e le l e c t r o -
phoresis, gels were stained with ethidium bromide,
and DNA was transferred to nylon membranes
(Amersham, Freiburg, Germany) according to the
manufacturer’s instructions using 20 · SSC.
2.4. Measurement of plaque areas
One-million CEC seeded in six-well plates were
infected with 100 plaque-forming units (PFU) of
the parental virus vRB-1B, the mutant virus
vPchTR
+/+ or the rescuant virus vPvTR
+/+.A td a y
5 p.i., cells were ﬁxed with 3% paraformaldehyde
for 15 min then permeabilized with 0.5% Triton
X-100 for 5 min. Cells were incubated in a blocking
solution (0.1% Triton X-100, 3% bovine serum albu-
min in phosphate buffered saline) at room tempera-
ture for 20 min. Indirect immunoﬂuorescence (IIF)
was performed with an anti-pp38 mouse antibody
011 [28, 30]f o l l o w e db yas e c o n d a r yg o a ta n t i -
mouse antibody labeled with Alexa Fluor 568 (Invit-
rogen). Digital images of 75 individual plaques were
obtained using an epiﬂuorescence Axiovert S100
inverted microscope and an AxioCam HRc digital
camera (Zeiss, Jena, Germany). Plaque areas were
measured using the National Institutes of Health Ima-
geJ software
1, and average plaque sizes and standard
deviations were determined for each virus.
2.5. In vitro viral replication
Virus growth curves were determined as previ-
ously described [25]. Brieﬂy, 1 · 10
6 CEC were
infected with approximately 100 PFU of parental or
mutant viruses. At 0, 24, 48, 72, 96, 120 and 144 h
p.i., monolayers were harvested and inoculated onto
fresh CEC in triplicate dishes. At day 5 p.i., plaques
were stained by IIF as described above. The mean
number of plaques was determined for each virus at
each time point. Two independent experiments were
performed.
2.6. Animal experiments
Commercial white leghorn speciﬁc pathogen-free
(SPF) chickens (Lohmann Tierzucht, Cuxhaven,
Germany)werehousedinisolationunits.Threegroups
of 1-day old chickens (n = 13) were inoculated
subcutaneouslywith1 000PFUofvRB-1B(group1),
the mutant vPchTR
+/+ (group 2) or the rescue virus
vPvTR
+/+ (group 3). Chickens were evaluated daily
for symptoms of MD, euthanized when clinical signs
were evident, and examined for gross MD lesions.
The experiment was terminated 8 weeks after
infection.
The number of viral DNA copies in chicken
blood was determined using quantitative PCR
(qPCR) assays. Whole blood obtained from the wing
vein of infected chickens on days 4, 7, 11, 18, 24, 32
and 42 p.i. was used for DNA extraction using the
E-Z 96 blood DNA kit (OMEGA bio-tek). Quantiﬁ-
cation of MDV genomic copies using qPCR was per-
formed as previously described [12, 39].
2.7. Relative quantiﬁcation of vTR expression
by qRT-PCR
TotalRNAwasextractedfrommock-infectedCEC
or cells infected with either vRB-1B, vPchTR
+/+,
vPvTR
+/+ or a virus in which both vTR copies were
deleted(vCR1-4
 / ,[ 36]usingtheRNeasyPlusMini
Kit (Qiagen, Hilden, Germany) according to the man-
ufacturer instructions. RNA integrity was electropho-
retically veriﬁed by ethidium bromide staining and
by OD260/OD280 nm absorption ratio > 1.95. RNA
was then used for qRT-PCR analysis of vTR expres-
sion using the TaqMan RNA-to-Ct 1-step kit (Applied
Biosystems, Darmstadt, Germany). The sequences
of primers (qRT-PCRvTR-Forw, qRT-PCRvTR-Rev)
and sequence of the vTR-probe are listed in Table I.
The qRT-PCR reaction consisted of 4 lLR N A
(1 lg), 1· TaqMan RT-PCR mix, 1· TaqMan RT
enzyme mix, 900 nM of each primer and 250 nM of
probeinaﬁnalvolumeof20 lL.Thefollowingexper-
imental run protocol was used: RT step (48  Cf o r
15 min), enzymein activation (95  C for 10 min), de-
naturation, ampliﬁcation/extension program repeated
40 times (95  C for 15 s, 60  Cf o r1m i n ) .A l lq R T -
PCRassayswereperformedinanABIPrism7500Fast
Real-TimePCRSystem(AppliedBiosystems),andthe
results were analyzed with the Sequence Detection
Systems version V2.0.3 software using the compara-
tive Ct method (2
 DDCt) of relative quantiﬁcation.
3. RESULTS
3.1. Construction of recombinant MDV
MDV contains in its genome two copies of
the vTR gene located in the BamHI L fragment,
1 http://rsb.info.nih.gov/ij/
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(page number not for citation purpose) Page 5 of 12which is found in both the TRL and IRL region
[7]. An MDV mutant, in which both copies of
the PvTR were replaced by the PchTR, was
generated from pRB-1B [26] using a two-step
Red-mediated mutagenesis strategy that allows
for markerless manipulation of BAC DNA as
previously described [35]. Genomic DNA of
each clone generated during each recombina-
tion step was then analyzed by PCR, restriction
fragment length polymorphism (RFLP) using
BamHI (data not shown) or PstId i g e s t i o na n d
by Southern blotting using probes speciﬁc for
the kanamycin cassette or the PchTR sequence.
Theoretical genomic modiﬁcations of BAC
DNA were conﬁrmed for each BAC clone
(Fig. 1). We could show that no spurious rear-
rangements occurred during the genetic manip-
ulation as shown by RFLP, although minor
sequence modiﬁcations or rearrangements
cannot formally be excluded. Similarly, revert-
ant BAC pPvTR
+/+ with two copies of PvTR
reinserted into the mutant pPchTR
+/+ was
generated following the same procedure and
analyzed with the same methods (Fig. 1).
3.2. PchTR induces low levels of vTR in vitro
In order to determine the effect on vTR
expression when PvTR is replaced with its
chicken counterpart PchTR, CEC were infected
with either vRB-1B, the mutant virus
vPchTR
+/+ or the rescuant vPvTR
+/+ virus. At
48 h p.i., total RNAwas extracted from infected
cells and used as a template for a qRT-PCR
analysis of vTR expression. At 48 h p.i., vTR
expression was 3-fold lower in cells infected
with the mutant virus when compared to that
in cells infected with parental vRB-1B or the
Figure 1. Restriction fragment length polymorphism and Southern blot analysis of recombinant MDV
BAC. DNA of pRB-1B and mutant BAC derived thereof was prepared, digested with PstI, and separated on
a 0.8% agarose gel together with 1-Kb marker (M, Promega) and a Dig-labeled marker (M-D). Southern
blot analysis was performed using PCR-generated digoxigenin-labeled probes using oligonucleotide primers
speciﬁc for the kanamycin cassette (middle panel) or the PchTR sequence (right panel).
Vet. Res. (2010) 41:56 N. Chbab et al.
Page 6 of 12 (page number not for citation purpose)rescuant virus (Fig. 2). In mock-infected cells
and in cells infected with a virus in which both
vTR copies were deleted, vCR1-4
 /  [36], vTR
expression was not detectable (Fig. 2). We con-
cluded that the PchTR has lower transcriptional
activity in avian cells than PvTR and that the
promoter was therefore not under the control
of a virus-derived factor.
3.3. vTR levels do not affect MDV replication
in vitro
Parental vRB-1B, mutant vPchTR
+/+ and the
vPvTR
+/+ viruses were assessed for in vitro
growth properties by analyzing plaque sizes
(Fig. 3A) and growth kinetics (Fig. 3B). Deter-
mination of the mean plaque areas demon-
strated that there was no discernable
difference when vPchTR and vPvTR
+/+ were
compared to vRB-1B (p =0 . 2 5a n dp =0 . 7 ,
respectively) (Fig. 3A). Similarly, growth kinet-
ics of the mutant vPchTR
+/+ virus were virtu-
ally indistinguishable from those of the
parental vRB-1B or the rescuant vPvTR
+/+
virus (Fig. 3B). From the results of the
in vitro growth properties of the generated
mutant viruses we concluded that the mutant
vPchTR
+/+ virus was similar to parental vRB-
1B with respect to the growth characteristics
in cultured cells and that vTR expression levels
do not inﬂuence MDV replication in vitro.
3.4. vTR levels do not affect MDV cytolytic
replication in vivo
The next series of experiments addressed
in vivo replication of vPchTR
+/+ in the natural
host. Three groups of 1-day-old chickens were
infected subcutaneously with either vRB-1B,
vPchTR
+/+ or vPvTR
+/+.O nd a y s4 ,7 ,1 1 ,1 4 ,
21, 28, 35 and 42 after infection, whole blood
samples were collected from infected animals.
Copy numbers of viral genomes were deter-
mined and the results are summarized in
Figure 4.B o t hv P c h T R
+/+ and vPvTR
+/+
viruses maintained virus replication rates virtu-
ally similar to those of vRB-1B, except that on
day 35 p.i. viremia levels were slightly higher
in birds infected with vPvTR
+/+ when com-
pared with those infected with the mutant or
the parental virus. However, the difference
was not statistically signiﬁcant (p =0 . 3 )a n d
vPvTR
+/+ viral loads reached values virtually
identical to those of wild-type and mutant
viruses at day 42 p.i. Taken together, the results
showed that replacement of PchTR in place of
PvTR in the genome of MDV does not impair
the ability of the mutant virus to replicate
in vivo.
3.5. Mutant MDV harboring the chTR
promoter is impaired in lymphoma
formation and dissemination
To investigate the role of vTR in MDV
induced lymphomagenesis, chickens infected
with either the vPchTR
+/+ mutant virus, the
parental virus vRB-1B or the rescuant virus
vPvTR
+/+ were monitored for clinical signs
and gross pathological lesions. MD incidence
was evaluated up to 56 days p.i. at which time
all surviving chickens were sacriﬁced and
examined for gross MD lesions. Infection with
vPchTR
+/+ induced a signiﬁcant reduction in
tumor incidence (46%, p < 0.05) in comparison
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Figure 2. Relative quantiﬁcation of vTR RNA in
infected CEC. CEC were mock infected (MI) or
infected with either the parental virus vRB-1B, the
mutant virus vPchTR
+/+, the rescuant virus
vPvTR
+/+ or a virus deleted for both vTR copies
(vCR1-4
 / ). At 48 h p.i., total RNAwas extracted
and used for qRT-PCR analysis of vTR expression.
Relative expression of vTR gene was normalized to
cellular GAPDH expression levels. Error bars
represent standard error of the mean of two
independent experiments at the 48 h time point.
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+/+ (85%). The dif-
ference in the percentage of birds developing
tumors after infection with vRB-1B (92%)
and vPvTR
+/+ (85%) was not signiﬁcant
(p = 0.56).
As regards to the pattern of lymphoma distri-
bution, we observed that tumors in the
vPchTR
+/+ group were less disseminated since
only 31% of chickens developed tumors at more
than two distinct organ sites relative to 84% in
the vRB-1B group and 54% in the revertant
group (Fig. 5). These results showed that
vPchTR
+/+ differs from vRB-1B and vPvTR
+/+
in terms of tumorigenic potential in the natural
host. Moreover, we could demonstrate that high
levels of vTR controlled by the virus promoter
are essential for MDV pathogenesis and can
inﬂuence disease progression.
4. DISCUSSION
MDVisamongthemostoncogenicherpesvi-
rusesknown[3]andtheonlyvirusknowntodate
that encodes its own telomerase RNA (vTR).
EvidenceregardingtheroleofvTRinpathogen-
esis [36] highlighted the importance of telome-
rase in cancer development but raised new
questions regarding the mechanism by which
expression of vTR contributes to oncogenesis.
FunctionalanalyseshaveshownthatvTRcan
reconstitute telomerase activity by interacting
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Figure 3. (A) Relative plaque sizes induced by vRB-1B, vPchTR
+/+ or rescuant virus vPvTR
+/+. CEC were
infectedwiththevirusesandatday5 p.i.cellswereanalyzedbyIIFwithanti-pp38MAb011andAlexaFluor
568 goat anti-mouse IgG (Molecular Probes). For each virus, 75 random plaques were photographed with a
digital camera (Axiovert 25 with Axiocam, Zeiss) and plaque sizes were determined using ImageJ software.
The mean plaque area of the wild type vRB-1B virus was set to 100%, and average relative plaque areas of
vPchTR
+/+andthevPvTR
+/+werecalculated.Meansandstandarddeviations(errorbars)aregiven.(B) Multi-
step growth kinetics of vRB-1B, vPchTR
+/+ and vPvTR
+/+. One-million CEC were infected with
approximately 100 PFU of the indicated virus. At the given times p.i., cells were trypsinized, titrated and
coseededwithfreshCEC.Atday5p.i.,cellswereﬁxed;permeabilizedandviralplaqueswerecountedafterIIF.
Meanvirustitersandstandarddeviations(errorbars)oftheresultsoftwoindependentexperimentsareshown.
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[7, 8]. Interestingly, telomerase activity during
MDV infection is increased in lymphocytes,
the target cells for transformation, and was asso-
ciated with high levels of vTR expression [33].
These data suggested that chTR is the limiting
factor and that high copy numbers of vTR are a
precondition for increasing telomerase activity
and promoting cell immortalization.
Regulation of telomerase activity varies
among vertebrates and is achieved through
TR and TERT expression at various levels such
as transcriptional control and subcellular locali-
zation of each component. Modulation of telo-
merase, which involves a complex network of
transcription factors and cis-acting sequences,
was mainly studied in model organisms and
man [22]. With respect to telomerase regulation,
the chicken has many features in common with
man such as age being associated with telomere
shortening [6] or telomerase downregulation in
most somatic cells and tissues during embry-
onic and postnatal development [34]. As
described for the hTR promoter, sequence anal-
ysis of the chTR and vTR promoter revealed
common transcription factor binding sites that
are involved in maintaining basal TR expres-
sion levels. Importantly, this analysis identiﬁed
cis elements speciﬁcally involved in vTR
transcriptional regulation including three
E-boxes and an EBS site [7, 33]. Existence of
additional transcription factor binding sites on
the vTR promoter implied other levels of con-
trol for vTR expression.
Our study aimed at determining whether
vTR promoter sequences are required for lym-
phomagenesis. To test this hypothesis, we used
the highly oncogenic RB-1B strain of MDV to
generate a mutant virus termed vPchTR
+/+ har-
boring the chicken TR promoter in lieu of the
vTR promoter. We showed by qRT-PCR that,
when compared with parental and revertant
viruses, vPchTR
+/+ had reduced levels of vTR
expression in culture cells conﬁrming that
vTR promoter has a stronger transcriptional
activity than its chicken counterpart (Fig. 2).
Additionally, we showed that vPchTR
+/+ repli-
cation was not impaired in vitro since
vPchTR
+/+ replicates with levels similar to
those of the parental and revertant viruses
(Fig. 3). This result further suggested that no
spurious rearrangement occurred during genetic
manipulation of the BAC DNA. Importantly,
in vivo replication of vPchTR
+/+ was also sim-
ilar to the wild-type and the rescuant viruses
(Fig. 4). Thus, our results correlate well with
those of Trapp et al. [36] who showed that
vTR expression is dispensable for MDV lytic
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Figure 4. High levels of vTR are dispensable for MDV cytolytic replication in vivo. Total DNA isolated
from whole blood samples taken at days 4, 7, 11, 14, 21, 28, 35 and 42 p.i. from chickens infected
with vPchTR
+/+, vPvTR
+/+ or the parental vRB-1B were used for qPCR analysis of the viral ICP4 gene and
a host gene (iNOS). Mean viral loads are given as copies of ICP4 per 1 · 10
6 copies of chicken iNOS.
No statistically signiﬁcant differences in viremia levels were observed between groups infected with
vPchTR
+/+, vPvTR
+/+ or vRB-1B. Graphs represented the means of 13 chickens per group and standard
deviations are given (error bars).
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indicating that vTR serves a role supporting
tumorigenesis rather than affecting tumorigene-
sis through a failure to efﬁciently replicate lyti-
cally. Consistent with this interpretation, our
in vivo experiment revealed that high levels
of vTR are essential for MDV pathogenesis
and for disease progression. Lymphomagenesis
in chickens infected with the vPchTR
+/+ mutant
was reduced by 54% in comparison to the wild-
type and rescuant viruses (Fig. 5). Moreover,
lesions in animals infected with the mutant
virus were smaller in size and less dissemi-
nated, results virtually identical to those
obtained earlier with vTR deletion mutants
[36]. Our data thus conﬁrm that vTR expression
is not only important for MDV lymphomagen-
esis but expression levels controlled by the
virus are necessary for its tumorigenic function.
vTR can result in increased telomerase activ-
ity in concert with chTERTin vitro [8]. In addi-
tion to the role of vTR in the telomerase
complex, some of its pro-oncogenic functions
seem to be independent of telomerase action.
Correlation between expression of vTR and its
oncogenic properties have been demonstrated
in DF-1 cells, in which telomerase activity is
undetectable. vTR expression led to morpho-
logical alterations in DF-1 cells similar to those
observed after expression of the bona ﬁde
MDVoncoprotein, Meq [36]. Meq is a nuclear
oncoprotein essential for MDV lymphomagene-
sis that acts as a regulator of transcription [21].
Depending on its dimerization partner, it can
induce either transcriptional activation or sup-
pression [18]. Like vTR, Meq is expressed dur-
ing both lytic and latent infection and higher
levels of Meq have been detected in tumor cells
and in lymphoid cell line transformed by MDV
[14, 27]. Interestingly, higher transcriptional
levels of Meq have also been associated with
higher levels of telomerase activity in lympho-
cytes and tumor formation in chickens. A previ-
ous mutational study of AP-1 site in the vTR
promoter did not have any effect on the tran-
scriptional activity of vTR promoter in MSB-
1 cells expressing Meq [33]. Consistent with
this data, attempts to identify Meq binding sites
on MDV genome through ChIP experiments
failed to identify Meq binding in the vTR pro-
moter [18]. Based on these results, it is conceiv-
able that Meq might indirectly transactivate
vTR expression through dimerization with one
of its cellular partners. It is notable that Meq/
c-Jun heterodimers transactivate c-Myc expres-
sion [18, 19, 23] and that c-Myc binding sites
are present on the vTR promoter. The presence
of E-Boxes in the vTR promoter is compatible
with a direct effect of proteins of the bHLH-Zip
superfamily like the Myc/Mad/Max transcrip-
tion factors that regulate many cellular func-
tions, including proliferation, differentiation,
and apoptosis. The ability of c-Myc to bind to
the vTR promoter and transactivate vTR gene
expression has been revealed in vitro by
54%
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31%
0 < 2 .> = 2
8%
8%
84%
15%
31%
54%
vRB-1B vPvTR+/+
vPchTR+/+
Figure 5. Mutant virus harboring two copies of the
chTR promoter is attenuated. Animals were inoc-
ulated subcutaneously with 1 000 PFU of either
vRB-1B, vPchTR
+/+ or vPvTR
+/+. During the
course of the experiment, moribund birds were
sacriﬁced and necropsied. At the end of the
experiment (8 weeks p.i.), surviving birds were
also necropsied and evaluated for MD. Morbidity
and lymphoma incidences were recorded. Lympho-
mas induced by mutant viruses harboring two
copies of the chTR promoter showed an altered
dissemination pattern within individual chickens.
The values correspond to the percentage of birds
infected with the indicated viruses, which failed to
develop lymphoma (0), in which less than (< 2) or
equal to or more than two sites of lymphoma
manifestation (greater or equal to 2) were observed.
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experiments also showed that endogenously
expressed c-Myc can interact with the vTR pro-
moter region containing E-Boxes 2 and 3 in
MSB-1 cells [33].
As mentioned earlier, MDV vTR is both a
lytic and a latent gene since it is expressed in
MDV-infected CEC and in MDV-transformed
lymphoblastoid cell lines [33, 36]. Semi-quanti-
tative RT-PCR analysis of vTR expression
showed that the level of vTR in lymphoid cells
is 17-fold higher than in CEC undergoing lytic
replication. The fact that c-Myc is also
expressed in both lytically and latently infected
cells strongly suggests that additional factors
are involved in vTR transcriptional activation.
Shkreli et al. suggested that Ets-1 might be a
factor involved in vTR transcriptional regula-
tion and analysis of the EBS site located on
vTR promoter sequence revealed the presence
of speciﬁc binding domain for three Ets pro-
teins, PU.1, Ets-1 and PEA3 [33]. However,
only Ets-1 appeared to be a potential candidate
because of high levels of Ets-1 expression in
lymphoid tissues in mature birds.
To conclude, we have shown here that
expression of vTR through its endogenous pro-
moter (PvTR) is essential for MDV lymphoma-
genesis. Further studies identifying the speciﬁc
vTR promoter elements causing increased lev-
els of vTR expression and their importance
in vivo will help delineate the pathogenesis of
MDV-induced deadly lymphoma.
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